Safety and vasopressor effect of rosuvastatin in septic patients | ||
| Egyptian Journal of Anaesthesia | ||
| Volume 30, Issue 3, July 2014, Pages 311-317 PDF (641.18 K) | ||
| DOI: 10.1016/j.egja.2014.02.005 | ||
| Authors | ||
| Hanaa A. El Gendy; Noha M. Elsharnouby | ||
| Abstract | ||
| Background Statins anti-inflammatory and antioxidant properties improve vascular function in septic patients. The aim of this prospective study was to assess vasopressor effect and safety of rosuvastatin therapy in septic patient. Methods One hundred and eight patients admitted to intensive care unit (ICU) with suspected or confirmed infection plus at least 2 systemic inflammatory response syndrome criteria were included in this prospective double-blinded randomized two groups’ parallel study. Group R received standard therapy and rosuvastatin 20 mg/day and Group C received standard therapy with placebo/day for 14 days. Results The number of ABPSPD was significantly increased 11(3) vs. 8 (3) ( = 0.0001), with a shorter time to initial ABPSPD 18(21) vs. 41(37) h ( = 0.0001) in Group R than Group C. Norepinephrine dose 0.8 (0.5) vs. 1.6 (0.6) and duration 3(2) vs. 6(3) were significantly reduced in Group R with no significant elevation in transaminases or CPK. Conclusions Rosuvastatin 20 mg/day in septic patients increased number ABPSPD, decreased time to initial ABPSPD, norepinephrine dose and duration, with no significant elevation in transaminases or CPK. | ||
|
Statistics Article View: 11 PDF Download: 12 |
||
